Martinsried/Munich – Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming investor and scientific conferences:
Harald von Boehmer Midwinter Conference 2019 International Immunobiology Symposium
Date: 19 – 23 January 2019
Location: Seefeld in Tirol, Austria
Guggenheim Healthcare Talks/Oncology Day
Date: 14 February 2019
Location: New York, USA
13th ODDO BHF German Conference
Date: 19 – 20 Februar 2019
Location: Frankfurt, Germany
CAR-TCR Summit Europe 2019
Date: 25 – 27 Februar 2019
Location: London, UK
Prof. Dolores Schendel, CEO and CSO of Medigene, will give a presentation on 26 February entitled “Next generation TCR-T cell therapies can offer improved safety and enhanced efficacy” and Dr. med. Kai Pinkernell, CMO and CDO of Medigene will talk about “Obtaining clinical trial authorisation for TCR-modified T cells in Germany” on 27 February.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,